Barbee MS, Ogunniyi A, Horvat TZ, Dang TO (2015) Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 49(8):907–937

Article  CAS  PubMed  Google Scholar 

Le Borgne-Rochet M, Angevin L, Bazellieres E, Ordas L, Comunale F, Denisov EV et al (2019) P-cadherin-induced decorin secretion is required for collagen fiber alignment and directional collective cell migration. J Cell Sci 132(21):233189

Article  Google Scholar 

Bruno TC (2020) New predictors for immunotherapy responses sharpen our view of the tumour microenvironment. Nature 577(7791):474–476

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4(2):118–132

Article  CAS  PubMed  Google Scholar 

Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF et al (2013) Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. J Cancer 4(9):736–754

Article  CAS  PubMed  PubMed Central  Google Scholar 

Facciabene A, Motz GT, Coukos G (2012) T-regulatory cells: key players in tumor immune escape and angiogenesis. Can Res 72(9):2162–2171

Article  CAS  Google Scholar 

Ferreira C, Lobo J, Antunes L, Lopes P, Jeronimo C, Henrique R (2018) Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features. Virchows Arch 473(4):443–452

Article  CAS  PubMed  Google Scholar 

Franzen O, Gan LM, Bjorkegren JLM (2019) PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database (oxford). https://doi.org/10.1093/database/baz046

Article  PubMed  PubMed Central  Google Scholar 

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6(269):pl1

Article  PubMed  PubMed Central  Google Scholar 

Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J et al (2014) Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 189(7):832–844

Article  CAS  PubMed  Google Scholar 

He K, Lv W, Zheng D, Cheng F, Zhou T, Ye S et al (2015) The stromal genome heterogeneity between breast and prostate tumors revealed by a comparative transcriptomic analysis. Oncotarget 6(11):8687–8697

Article  PubMed  PubMed Central  Google Scholar 

Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367–1380

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsiao TF, Wang CL, Wu YC, Feng HP, Chiu YC, Lin HY et al (2020) Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer. Clin Cancer Res 26:3220–3229

Article  CAS  PubMed  Google Scholar 

Hsu KH, Ho CC, Hsia TC, Tseng JS, Su KY, Wu MF et al (2015) Identification of five driver gene mutations in patients with treatment-Naive lung adenocarcinoma in Taiwan. PLoS ONE 10(3):e0120852

Article  PubMed  PubMed Central  Google Scholar 

Kwiatkowski DJ, Harpole DH Jr, Godleski J, Herndon JE 2nd, Shieh DB, Richards W et al (1998) Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 16(7):2468–2477

Article  CAS  PubMed  Google Scholar 

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS et al (2017) TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Can Res 77(21):e108–e110

Article  CAS  Google Scholar 

Li F, Wan B, Li XQ (2022) Expression profile and prognostic values of CDH family members in lung adenocarcinoma. Dis Markers 2022:9644466

PubMed  PubMed Central  Google Scholar 

Liu P, Weng Y, Sui Z, Wu Y, Meng X, Wu M et al (2016) Quantitative secretomic analysis of pancreatic cancer cells in serum-containing conditioned medium. Sci Rep 6:37606

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mizuno H, Kitada K, Nakai K, Sarai A (2009) PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2:18

Article  PubMed  PubMed Central  Google Scholar 

Ohtani H (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 7:4

PubMed  PubMed Central  Google Scholar 

Pan JH, Zhou H, Cooper L, Huang JL, Zhu SB, Zhao XX et al (2019) LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers. Front Immunol 10:6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC (2005) P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11(16):5869–5877

Article  CAS  PubMed  Google Scholar 

Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC (2007) P-cadherin expression in breast cancer: a review. Breast Cancer Res 9(5):214

Article  PubMed  PubMed Central  Google Scholar 

Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA (1999) P-cadherin expression in breast carcinoma indicates poor survival. Cancer-Am Cancer Soc 86(7):1263–1272

CAS  Google Scholar 

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752

Article  CAS  PubMed  Google Scholar 

Peyssonnaux C, Eychene A (2001) The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93(1–2):53–62

Article  CAS  PubMed  Google Scholar 

Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB et al (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9(2):166–180

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL (1987) Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317(15):929–935

Article  CAS  PubMed  Google Scholar 

Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC et al (2019) TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics 35(20):4200–4202

Article  CAS  PubMed  Google Scholar 

Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T et al (2012) The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22(11):2109–2119

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheng Q, D’Alessio JA, Menezes DL, Karim C, Tang Y, Tam A et al (2021) PCA062, a P-cadherin targeting antibody-drug conjugate, displays potent antitumor activity against P-cadherin-expressing Malignancies. Mol Cancer Ther 20(7):1270–1282

Article  CAS  PubMed  Google Scholar 

Sigel K, Makinson A, Thaler J (2017) Lung cancer in persons with HIV. Curr Opin HIV AIDS 12(1):31–38

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566

Article  CAS  PubMed  Google Scholar 

Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S et al (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18(3):378–381

Article  CAS  PubMed  Google Scholar 

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45(W1):W98–W102

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H et al (2005) Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Can Res 65(8):3092–3099

Article  CAS  Google Scholar 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108

Article